Method for amplification of endothelial progenitor cell in vitro
View Patent ↗The present invention provides a method for expanding an endothelial progenitor cell in vitro. More particularly, the present invention provides a method for culturing a hemangioblast comprising incubating a hemangioblast in a serum-free culture medium containing one or more factors selected from the group consisting of stem cell growth factor, interleukin-6, FMS-like tyrosine kinase 3 and thrombopoietin, and a vascular endothelial cell produced by the method; and a serum-free culture medium containing one or more factors selected from the group consisting of stem cell growth factor, interleukin-6, FMS-like tyrosine kinase 3 ligand and thrombopoietin, and a kit for the preparation of the serum-free culture medium and the like.
1. A method for preparing endothelial progenitor cells, which comprises incubating CD34 positive and/or CD133 positive cells in a serum-free culture medium containing stem cell factor, interleukin-6, FMS-like tyrosine kinase 3 ligand, thrombopoietin and vascular endothelial growth factor, whereby the number of endothelial progenitor cells contained in the CD34 positive and/or CD133 positive cells is increased.
2. The method of claim 1 , wherein the CD34 positive and/or CD133 positive cells include mononuclear cells including endothelial progenitor cells.
3. The method of claim 2 , wherein the CD34 positive and/or CD133 positive cells are prepared from bone marrow fluid, cord blood or peripheral blood.
4. The method of claim 1 , wherein the CD34 positive and/or CD133 positive cells include endothelial progenitor cells.
5. The method of claim 4 , wherein the CD34 positive and/or CD133 positive cells are prepared from bone marrow fluid, cord blood or peripheral blood.
6. The method of claim 1 , wherein the CD34 positive and/or CD133 positive cells, stem cell factor, interleukin-6, FMS-like tyrosine kinase 3 ligand, thrombopoietin, and vascular endothelial growth factor are all obtained from animals of a single species.
7. The method of claim 1 , wherein the CD34 positive and/or CD133 positive cells are derived from human.
8. The method of claim 1 , wherein the serum-free culture medium further comprises transforming growth factor β inhibitor.